PFE241108C40000
- 0.01
- 0.000.00%
Pfizer Newsroom
We Want YOU to Submit Questions for Election Night
Unusual Options Activity: COIN, NXPI and Others Attract Market Bets, COIN V/OI Ratio Reaches 130.0
Market Climbs for Election Day Excitement | Live Stock
Pfizer Management to Meet With Jefferies
Profit From Pfizer's (PFE) Post-Earnings Lull With a Short Iron Condor
Peering Into Pfizer's Recent Short Interest
Pfizer (PFE.US) PARP inhibitor "talazoparib" approved for marketing.
On November 5th, the National Medical Products Administration (NMPA) official website shows that pfizer (PFE.US)'s application for marketing approval of talazoparib has been approved.
Pfizer's Ponsegromab: A Promising Yet Uncertain Opportunity Influencing Hold Rating
Monday Market Moves Sideways, Election and FOMC in Sight | Wall Street Today
Pfizer | 10-Q: Q3 2024 Earnings Report
Why Nvidia Stock Is Less Important Than Sherwin-Williams for the Dow Jones Industrial Average
Buy, Sell or Hold Pfizer Stock After Q3 Earnings Beat, Guidance Boost?
Unusual Options Activity: BBY, MRVL and Others Attract Market Bets, BBY V/OI Ratio Reaches 100.5
BioNTech Sees Full-Year Revenue at Low End of Guidance; Third-Quarter Results Rise
Monday Market Mixed Before Crazy, Pivotal Week | Live Stock
Analysts Adjust Pfizer Projections, Citing Uncertain Q4 Outlook
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
Evercore Maintains Pfizer(PFE.US) With Buy Rating
Truist Financial Maintains Pfizer(PFE.US) With Buy Rating
Pfizer (PFE) Gets a Buy From Truist Financial